• Homoharringtonine: Cytotoxic Alkaloid Applications in Cancer

  2026-08-04

  Homoharringtonine stands at the intersection of cancer biology and antiviral research, offering robust experimental workflows for both leukemia and SARS-CoV-2 studies. This article translates breakthrough findings into actionable protocols and troubleshooting strategies, maximizing reproducibility and translational impact.

• Plant Cell Lysis Buffer for WB and IP: Advanced Workflows &

  2026-08-04

  Unlock reproducible, high-yield protein extraction from challenging plant tissues using Plant Cell Lysis Buffer for WB and IP. This specialized buffer from APExBIO streamlines Western blotting and immunoprecipitation, preserving native interactions and enabling robust translational research. Dive into best-practice protocols, troubleshooting, and the impact of protocol fidelity on breakthrough studies like MAPK10/KRT16 signaling in cancer.

• O-propargyl-puromycin (OPP): Illuminating Mitochondrial Regu

  2026-08-03

  Discover how O-propargyl-puromycin (OPP) uniquely enables high-resolution mapping of protein synthesis in B cells—directly connecting mitochondrial integrity, antibody production, and advanced proteomics research. This article delivers a distinctive, mechanistic perspective for scientists seeking to optimize translation assays.

• Mutational Landscape of Myeloma Cell Lines: Implications for

  2026-08-03

  This study delivers the first comprehensive whole-exome analysis of human multiple myeloma cell lines, revealing critical mutated genes and pathways linked to disease progression and therapy resistance. These findings refine model selection in experimental myeloma research and support more targeted investigation of drug responses.

• Z-IETD-FMK: Precision Caspase-8 Inhibition in Immune Researc

  2026-08-02

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) unlocks advanced control of apoptosis and T cell proliferation, offering reliable modulation of NF-κB signaling and TRAIL-mediated apoptosis across immune and cancer models. This article translates the latest mechanistic insights and workflow protocols into actionable guidance for researchers seeking high specificity and reproducibility.

• Innovations in In Vitro Drug Response Metrics for Cancer Res

  2026-08-01

  Schwartz's dissertation introduces improved in vitro methods for distinguishing between cancer cell growth inhibition and cell death, challenging the traditional use of relative viability as a singular drug response metric. These insights facilitate more precise evaluation of multikinase inhibitors, such as Foretinib (GSK1363089), in preclinical cancer research.

• Cy3 NHS Ester (Non-Sulfonated): Technical Guide for Biomolec

  2026-07-31

  Cy3 NHS ester (non-sulfonated) provides a reliable solution for fluorescent labeling of amino groups in proteins, peptides, and oligonucleotides, enabling sensitive detection in biomedical imaging and quantitative assays. It is best suited for workflows compatible with organic co-solvents and immediate use, but is not recommended for labeling sensitive proteins under water-only conditions or for protocols requiring long-term storage of dye solutions.

• Omeprazole (A2845): Technical Use in Gastric Acid Research

  2026-07-31

  Omeprazole (SKU A2845) is a research-grade H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton pump inhibition, and antiulcer activity in preclinical laboratory models. It should not be used in diagnostic or medical settings and is optimized for mechanistic workflows requiring precise assay control and compound stability.

• Cell Division Dynamics Refine Tissue Boundaries in Drosophil

  2026-07-30

  This study demonstrates that cell divisions in the Drosophila embryo not only challenge but actively refine tissue boundaries by increasing tissue fluidity and modulating junctional tension. The findings provide a mechanistic framework for understanding how tissue organization is maintained and dynamically regulated, with implications for developmental biology and cancer research.

• IWP-L6: Redefining Porcupine Inhibition in Metabolic and Dev

  2026-07-30

  Explore IWP-L6, a highly potent Porcupine inhibitor, and discover how its unique mechanism advances Wnt signaling modulation in metabolic and developmental biology. This article delivers a comparative, mechanistic, and translational analysis not covered elsewhere.

• ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibito

  2026-07-29

  This study identifies that high-grade glioma cells deficient in ATRX—a chromatin remodeler commonly mutated in gliomas—are markedly more sensitive to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. The findings highlight the potential of stratifying glioma therapies based on ATRX mutation status and propose combinatorial regimens with standard alkylating agents to enhance treatment efficacy.

• ERAD-Hijacking Chimeras for Selective Degradation of TM Prot

  2026-07-29

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule technology that leverages the ER-associated degradation pathway for efficient and selective degradation of transmembrane proteins. This advance addresses persistent challenges in targeted protein degradation and has significant implications for both mechanistic research and therapeutic development.

• Reversine: Practical Guidance for Aurora Kinase Inhibition

  2026-07-28

  Reversine is a small molecule Aurora kinase inhibitor used primarily in cancer biology research to dissect mitotic checkpoint regulation and cell cycle control. It is suitable for in vitro and in vivo applications involving cancer cell proliferation inhibition, particularly in cervical cancer models. Reversine is not intended for diagnostic or therapeutic use, and its application should be limited to scientific research environments.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Workflow Guide

  2026-07-28

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody enables high-sensitivity detection and visualization of mouse primary antibodies in fluorescence-based immunoassays. It is optimized for workflows such as immunofluorescence, flow cytometry, and western blotting, but is not intended for diagnostic or clinical applications. Use is restricted to research settings targeting mouse IgG.

• Selective β1 Blockade Spares Hematopoietic Recovery After HC

  2026-07-27

  This study demonstrates that nonselective β-adrenergic receptor blockers, but not β1-selective agents such as Metoprolol Tartrate, impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in both mice and humans. The findings clarify the receptor-specific roles of adrenergic signaling in post-transplant bone marrow recovery and inform the design of cardiovascular interventions in transplant settings.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page